466 reports of this reaction
3.2% of all MICONAZOLE NITRATE reports
#6 most reported adverse reaction
VAGINAL HAEMORRHAGE is the #6 most commonly reported adverse reaction for MICONAZOLE NITRATE, manufactured by H E B. There are 466 FDA adverse event reports linking MICONAZOLE NITRATE to VAGINAL HAEMORRHAGE. This represents approximately 3.2% of all 14,417 adverse event reports for this drug.
Patients taking MICONAZOLE NITRATE who experience vaginal haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VAGINAL HAEMORRHAGE is moderately reported among MICONAZOLE NITRATE users, representing a notable but not dominant share of adverse events.
In addition to vaginal haemorrhage, the following adverse reactions have been reported for MICONAZOLE NITRATE:
The following drugs have also been linked to vaginal haemorrhage in FDA adverse event reports:
VAGINAL HAEMORRHAGE has been reported as an adverse event in 466 FDA reports for MICONAZOLE NITRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VAGINAL HAEMORRHAGE accounts for approximately 3.2% of all adverse event reports for MICONAZOLE NITRATE, making it a notable side effect.
If you experience vaginal haemorrhage while taking MICONAZOLE NITRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.